Loading organizations...
Key people at Tessera, Inc..
Tessera Therapeutics pioneers Gene Writing™, a novel approach to genome engineering designed to integrate therapeutic messages directly into the human genome. This versatile technology platform facilitates both small and large-scale permanent alterations to genetic code, complemented by non-viral delivery systems for targeted genomic modifications. The company’s core focus is on developing precise biological tools to treat the root causes of disease.
The company was founded by Flagship Pioneering, with key contributions from Geoffrey von Maltzahn and Jacob Rubens, who serve as co-founders. Their foundational insight centered on the potential to develop an entirely new class of genetic medicines, moving beyond traditional gene editing to actively "write" new genetic information into living cells, thus establishing a fresh paradigm for treating serious illnesses.
Tessera Therapeutics aims to serve patients globally who suffer from conditions with significant unmet medical needs. The company's vision is to cure disease by fundamentally rewriting the code of life, developing therapies that are not only curative but also broadly accessible. They are dedicated to expanding the possibilities of genetic medicine for widespread patient benefit.
Key people at Tessera, Inc..
Tessera, Inc., founded in 1990, was a pioneering semiconductor company specializing in chip-scale packaging technologies that enabled miniaturization for electronics like smartphones and imaging devices, broadly licensing its intellectual property to industry leaders.[1][3][5] It evolved through acquisitions—such as FotoNation in 2008 for image enhancement and DTS in 2016 for audio tech—before rebranding as Tessera Holding Corporation, then Xperi Corporation in 2017, and ultimately splitting into Xperi Inc. (product operations) and Adeia Inc. (IP licensing) in 2022, serving billions of devices via premium audio, imaging, and packaging solutions.[1][2][3][4]
(Note: A separate, unrelated Tessera—formerly Skookum, rebranded in 2025—focuses on employment for people with disabilities in government and manufacturing contracts, but lacks evidence of being a tech startup or investment firm.[2] Another entity, Tessera Therapeutics, is a 2018 biotech startup, distinct from the semiconductor Tessera, Inc.[9])
Tessera, Inc. emerged in 1990, focusing on research and development of advanced semiconductor packaging to make chips smaller, faster, and more efficient, incorporated in Delaware ahead of its 2003 IPO as Tessera Technologies, Inc. on Nasdaq (TSRA) at $13 per share with 84 employees.[1][3][7][8] Key early milestones included developing broadly licensed chip-scale packaging, pivotal for the semiconductor boom in mobile computing and imaging.[1][5][6] The company expanded via strategic buys: FotoNation in 2008 for computational imaging, DTS (including HD Radio) in 2016, leading to the 2017 name change to Xperi to reflect its broadened portfolio in audio, vision, and interconnect tech under subsidiaries like Invensas (founded 2011).[1][3][4]
Tessera rode the 1990s-2010s semiconductor miniaturization wave, fueling the smartphone revolution and rise of compact electronics amid Moore's Law pressures for denser, efficient chips.[1][5][6] Its timing aligned with explosive demand for mobile imaging and audio in devices from top OEMs, while market forces like IP monetization favored licensing over fabrication in a capital-intensive industry.[3][4] By influencing standards in packaging and interconnects, Tessera shaped ecosystem scalability, paving the way for modern AI edge computing and 5G, though its evolution into Xperi/Adeia reflects ongoing consolidation in IP-driven tech licensing.[1]
Tessera's legacy as a semiconductor IP pioneer endures through its successors Xperi Inc. (NYSE: XPER) and Adeia Inc. (Nasdaq: ADEA), positioned for growth in AI-enhanced imaging, immersive audio, and next-gen packaging amid surging demand for edge AI and AR/VR devices. Trends like 6G, automotive semiconductors, and sustainable miniaturization will propel their licensing revenue, potentially expanding via further acquisitions or spin-offs. Their influence may evolve toward dominating IP in human-centric tech experiences, building on a foundation that powered billions of connected products—much like their chip-scale origins transformed electronics at scale.[1][3][4]
